AnGes has been granted a patent for a non-naturally occurring composition containing a CRISPR nuclease with a specific amino acid sequence and nuclear localization sequences. This innovation could have significant implications for genetic research and therapeutic applications. GlobalData’s report on AnGes gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on AnGes, NSAID cancer drugs was a key innovation area identified from patents. AnGes's grant share as of May 2024 was 34%. Grant share is based on the ratio of number of grants to total number of patents.
Crispr nuclease composition with nuclear localization sequences
A recently granted patent (Publication Number: US11946077B2) discloses a non-naturally occurring composition involving a CRISPR nuclease with specific characteristics. The composition includes a CRISPR nuclease with a sequence having at least 90% identity to a specified amino acid sequence, along with one or more nuclear localization sequences (NLSs). Additionally, the composition may contain RNA molecules, such as CRISPR RNA (crRNA) molecules or single-guide RNA (sgRNA) molecules, which can form complexes with the CRISPR nuclease and target specific sites.
Furthermore, the patent claims cover methods for modifying nucleotide sequences in cell-free systems or cell genomes using the disclosed composition. The CRISPR nuclease, in conjunction with RNA molecules, is utilized to induce DNA breaks at specific sites, facilitating targeted modifications. The methods outlined in the patent encompass various scenarios, including the introduction of the CRISPR nuclease and RNA molecules as a ribonucleoprotein (RNP) complex, highlighting the versatility and specificity of the disclosed composition in genome editing applications.
To know more about GlobalData’s detailed insights on AnGes, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
